Prostate Cancer – NCI-05-C-0191
Dr. Aradhana Kaushal
Principal Investigator
NCI is currently conducting the following trial for patients with prostate cancer. Click on the trial below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact Dr. Camphausen and his staff directly.
You may also call the Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937) to inquire about referring a patient to this trial.
- Participants undergo MRI imaging and biopsies from the site of interest
- A fiducial marker will be left at the biopsy site to direct future radiation therapy
- Areas of the prostate with pathologically confirmed malignancy will undergo dose escalation with IMRT
- Areas of the prostate with abnormalities not available for biopsy or without definite pathologic evidence of disease will receive intermediate doses; remainder of the prostate gland will receive standard dose
- Participants will be evaluated at 2, 4, 8, and 12 weeks for acute effects of radiation therapy upon completion of therapy
- Patients will be evaluated at 6, 9, 12, 18 and every 6 months afterward for late effects until 36 months; thereafter, follow-ups will be once a year until for 5 years
Why is this trial important?
This trial applies a new technology called intensity modulated radiation therapy (IMRT) to treat the prostate in patients with localized prostate cancer. IMRT is more precise than standard radiation treatment. Therefore, IMRT can treat areas of cancer within the prostate to a higher dose while treating the rest of the normal prostate to tissue to standard doses. Higher radiation doses have previously been shown to improve outcomes in patients with prostate cancer. The treatment plan in this study has the potential to improve survival while actually maintaining a low level of side effects.
Back to Top
